Abbott Coughs Up $23M To Settle Patent Fraud Claims

Law360, New York (January 7, 2010, 5:02 PM EST) -- Abbott Laboratories and French partner Fournier Industrie et Sante have agreed to pay 23 states and the District of Columbia $22.5 million to settle claims that the drug companies blocked generics makers from breaking into the market for cholesterol drug TriCor by filing meritless patent infringement suits.

The settlement — announced Thursday by attorneys general across the U.S. — resolves litigation in the U.S. District Court for the District of Delaware and provides that certain state and local governmental purchasers, including public hospitals and health departments,...
To view the full article, register now.